Literature DB >> 8113961

Potential neurotoxicity of the solvent vehicle for cyclosporine.

A J Windebank1, M D Blexrud, P C de Groen.   

Abstract

Nervous system complications resulting from i.v. administration of cyclosporine (CS) are especially frequent in liver transplant recipients. Because CS is insoluble in water, the i.v. preparation is formulated in a polyoxyethylated castor oil and ethyl alcohol. Rat dorsal root ganglion neurons exposed in vitro to the i.v. preparation exhibited axonal swelling and degeneration. No effect of CS (dissolved directly in serum) was seen on testing individual components of the i.v. solution. However, 0.1% polyoxyethylated castor oil (volume of solute/volume of solvent) produced axonal swelling and degeneration and 0.001% polyoxyethylated castor oil produced demyelination in vitro. Polyoxyethylated castor oil is manufactured by reacting castor oil with ethylene oxide, and we speculate that residual ethylene oxide or a polymerization product may be responsible for the in vitro neurotoxicity. Although little is known about the pharmacokinetics of polyoxyethylated castor oil, plasma levels of 0.001 to 0.01% polyoxyethylated castor oil (volume of solute/volume of solvent) are probably achieved with therapeutic doses of the i.v. CS preparation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8113961

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

Review 2.  Immunosuppressive and anti-inflammatory properties of engineered nanomaterials.

Authors:  A N Ilinskaya; M A Dobrovolskaia
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

Review 3.  Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes.

Authors:  Liza C Villaruz; Mark A Socinski
Journal:  Eur J Cancer       Date:  2016-02-12       Impact factor: 9.162

4.  Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids.

Authors:  Junping Wang; Dimitry Mongayt; Vladimir P Torchilin
Journal:  J Drug Target       Date:  2005-01       Impact factor: 5.121

5.  Adsorption and Leachable Contamination of Flucloxacillin, Cyclosporin and Amiodarone Following Delivery Through an Intravenous Administration Set.

Authors:  Zachary Woodward; Peter Brooks; Bernadette Morris-Smith; Marianne Wallis; Steven M Ogbourne
Journal:  Pharm Res       Date:  2018-04-19       Impact factor: 4.200

Review 6.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice.

Authors:  José Hureaux; Frédéric Lagarce; Frédéric Gagnadoux; Marie-Christine Rousselet; Valérie Moal; Thierry Urban; Jean-Pierre Benoit
Journal:  Pharm Res       Date:  2010-03       Impact factor: 4.200

8.  Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer.

Authors:  Francesco Di Costanzo; Silvia Gasperoni; Virginia Rotella; Federica Di Costanzo
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

9.  Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats.

Authors:  N Authier; J P Gillet; J Fialip; A Eschalier; F Coudore
Journal:  Neurotox Res       Date:  2001-07       Impact factor: 3.911

10.  Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives.

Authors:  Charity D Scripture; William D Figg; Alex Sparreboom
Journal:  Curr Neuropharmacol       Date:  2006-04       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.